The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | Updates in DLBCL from ASH 2021
Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, shares some of the most exciting data in diffuse large B-cell lymphoma (DLBCL) presented at ASH 2021. To begin with, three randomized clinical trials compared chimeric antigen receptor (CAR) T-cell therapy to standard of care (SOC) in the second-line setting. The TRANSFORM (NCT03575351) and the ZUMA-7 (NCT03391466) trials reported positive results while the BELINDA trial (NCT03570892) did not meet its primary endpoint. Nevertheless, these trials suggest CAR-T therapy as a new potential SOC in the second-line setting. In addition, there were some updates in treatments for high-risk DLBCL in the first-line setting. According to Dr Kamdar, the focus now should be on moving immunotherapy earlier in the treatment of patients with high-risk DLBCL. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
